Factors Affecting Valrubicin Response in Patients with Bacillus Calmette-Guérin–Refractory Bladder Carcinoma in Situ

References

• . Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300
   PubMed Web of Science ®Google Scholar
• . Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH. The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int. 2010;105(3):300–308
   PubMed Web of Science ®Google Scholar
• . Kirkali Z, Chan T, Manoharan M,. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66(6 suppl 1):4–34
   PubMed Web of Science ®Google Scholar
• . Pelucchi C, Bosetti C, Negri E, Malvezzi M, La Vecchia C. Mechanisms of disease: the epidemiology of bladder cancer. Nat Clin Pract Urol. 2006;3(6):327–340
   PubMedGoogle Scholar
• . Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer. 2000;89(3):630–639
   PubMed Web of Science ®Google Scholar
• . Lammers RJ, Witjes JA. Developments in intravesical therapy for non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2010;10(12):1903–1916
   PubMed Web of Science ®Google Scholar
• . Montie JE, Clark PE, Agerwal N,. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™): bladder cancer, version 2. 2011. Fort Washington, PA: National Comprehensive Cancer Network; 2011
   Google Scholar
• . Persad R, Lamm D, Brausi M,. Current approaches to the management of non-muscle invasive bladder cancer: comparison of current guidelines and recommendations. Eur Urol. 2008;7( suppl):637–650
   Google Scholar
• . Rischmann P, Desgrandchamps F, Malavaud B, Chopin DK. BCG intravesical instillations: recommendations for side-effects management. Eur Urol. 2000;37( suppl 1):33–36
   PubMed Web of Science ®Google Scholar
• . Gontero P, Bohle A, Malmstrom PU,. The role of bacillus Calmette-Guerin in the treatment of non-muscle-invasive bladder cancer. Eur Urol. 2010;57(3):410–429
   PubMed Web of Science ®Google Scholar
• . Yates DR, Roupret M. Failure of bacille Calmette-Guerin in patients with high risk non-muscle-invasive bladder cancer unsuitable for radical cystectomy: an update of available treatment options. BJU Int. 2010;106(2):162–167
   PubMedGoogle Scholar
• . Malmstrom PU, Sylvester RJ, Crawford DE,. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247–256
   PubMed Web of Science ®Google Scholar
• . DeVeale B, Brummel T, Seroude L. Immunity and aging: the enemy within? Aging Cell. 2004;3(4):195–208
   PubMedGoogle Scholar
• . Prout GR Jr, Wesley MN, Yancik R, Ries LA, Havlik RJ, Edwards BK. Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study. Cancer. 2005;104(8):1638–1647
   PubMed Web of Science ®Google Scholar
• . Kim JC, Steinberg GD. Medical management of patients with refractory carcinoma in situ of the bladder. Drugs Aging. 2001;18(5):335–344
   PubMedGoogle Scholar
• . Valstar (valrubicin) [package insert]. Chadds Ford, PA: Endo Pharmaceuticals Inc; 2009
   Google Scholar
• . Blum RH, Garnick MB, Israel M, Panellos GP, Henderson IC, Frei E 3rd. Preclinical rationale and phase I clinical trial of the adriamycin analog, AD 32. Recent Results Cancer Res. 1981;76:7–15
   PubMedGoogle Scholar
• . Greenberg RE, Bahnson RR, Wood D,. Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology. 1997;49(3):471–475
   PubMedGoogle Scholar
• . Ignatoff JM, Chen YH, Greenberg RE, Pow-Sang JM, Messing EM, Wilding G. Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group. Urol Oncol. 2009;27(5):496–501
   PubMedGoogle Scholar
• . Patterson AL, Greenberg RE, Weems L,. Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. Urology. 2000;56(2):232–235
   PubMed Web of Science ®Google Scholar
• . Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000;163(3):761–767
   PubMed Web of Science ®Google Scholar
• . Sfakianos J, Shariat SF, Favaretto RL, Rioja J, Herr HW. Impact of smoking on outcomes after intravesical bacillus Calmette-Guerin therapy for urothelial carcinoma not invading muscle of the bladder [published online ahead of print November 29, 2011]. BJU Int.
   Google Scholar
• . Parsons CL. The role of the urinary epithelium in the pathogenesis of interstitial cystitis/prostatitis/urethritis. Urology. 2007;69( 4 suppl):9–16
   PubMed Web of Science ®Google Scholar
• . Teichman JM, Moldwin R. The role of the bladder surface in interstitial cystitis/painful bladder syndrome. Can J Urol. 2007;14(4):3599–3607
   PubMedGoogle Scholar
• . Sweatman TW, Payne C, Patterson L, Byers K, Koseki Y, Israel M. Penetration of intravesical (ive) N-trifluoroacetyladriamycin-14-valerate (AD 32) into human urinary bladder tissue: a clinical pharmacology study [abstract #1247]. Proc Am Assoc Cancer Res. 1996;37:182
   Google Scholar
• . Filion MC, Filion B, Reader S, Ménard S, Phillips NC. Modulation of interleukin-12 synthesis by DNA lacking the CpG motif and present in a mycobacterial cell wall complex. Cancer Immunol Immunother. 2000;49(6):325–334
   PubMedGoogle Scholar
• . Filion MC, Lepicier P, Morales A, Phillips NC. Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells. Br J Cancer. 1999;79(2):229–235
   PubMed Web of Science ®Google Scholar
• . Morales A, Chin JL, Ramsey EW. Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. J Urol. 2001;166(5):1633–1637; discussion 1637–1638
   PubMed Web of Science ®Google Scholar
• . Morales A, Phadke K, Steinhoff G. Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed. J Urol. 2009;181(3):1040–1045
   PubMed Web of Science ®Google Scholar